Immatics NV opened lower at $6.64, compared with its previous close of $6.69. In the last trading session, the stock traded between $6.33 and $6.89. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Immatics NV is now worth
$ 56.44
Resulting in a loss of
$ 43.56 (43.56%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.18 (-2.65%)
Day High
$6.89
Day Low
$6.33
Day Open
$6.64
Prev Close
$6.69
Volume
6,51,157
1W Return
-5.55%
1M Return
-9.49%
3M Return
-33.17%
6M Return
-43.56%
1Y Return
-29.13%
Fundamentals
Market Cap ($ Mn)
975
PE Ratio
-
PB Ratio
2.82
PEG Ratio
-
ROE
-39.66%
ROCE
-39.76%
EPS (TTM)
$-0.48
Investment Returns
1 Week
-5.55%
1 Month
-9.49%
3 Months
-33.17%
6 Months
-43.56%
9 Months
-36.46%
Financials
Quarterly
All values in $ Mn
18.6
Mar 25
4.7
Jun 25
5.2
Sep 25
19.8
Dec 25
9.1
Jun 26
6.9
Sep 26
Updates
10Nov
Immatics Q3FY26 Results: EPS misses estimate, net loss widens 51% YoY
Net loss widened 50.6% YoY to $86.3 million in Q3FY26. Revenue of $7.968 million missed analyst estimate of $10.230 million by 22.1%. EPS of $(0.58) missed consensus estimate of $(0.49) by 18.4%. Cash position stands at $536.3 million, funding operations into Q4 2028.
2 days ago
26Oct
Immatics reports 32% response rate for IMA402 in melanoma at ESMO 2026
IMA402 bispecific achieved a 32% confirmed objective response rate in PRAME-high advanced melanoma patients. Median duration of response for IMA402 was 12.5 months with a 91% one-year overall survival rate. IMA203CD8 cell therapy demonstrated a 55% cORR in heavily pretreated gynecologic cancers. Safety profiles remained favorable with no ICANS or Grade 5 treatment-related adverse events reported.
17 days ago
25Aug
Immatics agrees to $150M share and warrant offering
Immatics agrees to sell 12.9 million shares and 4.3 million pre-funded warrants. Gross proceeds from the underwritten offering are expected to be $150 million. Jefferies, Leerink Partners, and Cantor act as joint book-running managers. Offering closes on August 26, 2026, subject to customary conditions.
2mo ago
18Aug
Immatics Q2 Results: EPS misses estimate, sales up 93% YoY
Immatics Q2 financials reveal a complex picture of growth versus expectation. While sales surged 93.27% YoY to $10.630M and losses narrowed 19.7% to $(0.53) per share, both key metrics significantly missed analyst estimates. Revenue fell 27.14% short of the $14.590M forecast, and EPS missed the $(0.43) target by 23.26%, highlighting a gap between actual performance and market sentiment.
2mo ago
17Jul
Immatics to present PRAME franchise data at ESMO 2026
Immatics N.V. is set to showcase its PRAME franchise at the ESMO Congress 2026 with three presentations covering anzu-cel, IMA203CD8, and IMA402. The data spans Phase 1 and Phase 1b trials across various solid tumors, including melanoma and gynecologic cancers. Abstracts will be released on October 19, 2026.
